Invivyd Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.84
- Today's High:
- $1.91
- Open Price:
- $1.84
- 52W Low:
- $0.98
- 52W High:
- $4.74
- Prev. Close:
- $1.83
- Volume:
- 154893
Company Statistics
- Market Cap.:
- $200.85 million
- Book Value:
- 2.57
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.9%
- Return on Equity TTM:
- -50.32%
Company Profile
Invivyd Inc. had its IPO on 2021-08-06 under the ticker symbol IVVD.
The company operates in the Healthcare sector and Biotechnology industry. Invivyd Inc. has a staff strength of 84 employees.
Stock update
Shares of Invivyd Inc. opened at $1.84 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.84 - $1.91, and closed at $1.89.
This is a +3.28% increase from the previous day's closing price.
A total volume of 154,893 shares were traded at the close of the day’s session.
In the last one week, shares of Invivyd Inc. have increased by +3.28%.
Invivyd Inc.'s Key Ratios
Invivyd Inc. has a market cap of $200.85 million, indicating a price to book ratio of 0.4995 and a price to sales ratio of 0.
In the last 12-months Invivyd Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-165468000. The EBITDA ratio measures Invivyd Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Invivyd Inc.’s operating margin was 0% while its return on assets stood at -25.9% with a return of equity of -50.32%.
In Q2, Invivyd Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Invivyd Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.6 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Invivyd Inc.’s profitability.
Invivyd Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.8205. Its price to sales ratio in the trailing 12-months stood at 0.
Invivyd Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $315.41 million
- Total Liabilities
- $32.51 million
- Operating Cash Flow
- $32.60 million
- Capital Expenditure
- $9000
- Dividend Payout Ratio
- 0%
Invivyd Inc. ended 2024 with $315.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $315.41 million while shareholder equity stood at $281.56 million.
Invivyd Inc. ended 2024 with $0 in deferred long-term liabilities, $32.51 million in other current liabilities, 11000.00 in common stock, $-618975000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $121.95 million and cash and short-term investments were $298.43 million. The company’s total short-term debt was $1,611,000 while long-term debt stood at $0.
Invivyd Inc.’s total current assets stands at $309.99 million while long-term investments were $0 and short-term investments were $176.48 million. Its net receivables were $474000.00 compared to accounts payable of $4.11 million and inventory worth $-474000.00.
In 2024, Invivyd Inc.'s operating cash flow was $32.60 million while its capital expenditure stood at $9000.
Comparatively, Invivyd Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.89
- 52-Week High
- $4.74
- 52-Week Low
- $0.98
- Analyst Target Price
- $2.5
Invivyd Inc. stock is currently trading at $1.89 per share. It touched a 52-week high of $4.74 and a 52-week low of $4.74. Analysts tracking the stock have a 12-month average target price of $2.5.
Its 50-day moving average was $1.55 and 200-day moving average was $1.59 The short ratio stood at 8.68 indicating a short percent outstanding of 0%.
Around 2549% of the company’s stock are held by insiders while 7328.9% are held by institutions.
Frequently Asked Questions About Invivyd Inc.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.